Media headlines about Karyopharm Therapeutics (NASDAQ:KPTI) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Karyopharm Therapeutics earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.4033042685191 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Insider Selling: Karyopharm Therapeutics (KPTI) CEO Sells 10,000 Shares of Stock (americanbankingnews.com)
- Karyopharm Therapeutics (KPTI) Expected to Post Earnings of -$0.82 Per Share (americanbankingnews.com)
- MetroWest Business Digest for May 20, 2018 (metrowestdailynews.com)
- Jefferies Group Analysts Reduce Earnings Estimates for Karyopharm Therapeutics (KPTI) (americanbankingnews.com)
- Karyopharm Therapeutics (KPTI) to Present Selinexor Phase 1b/2 STOMP Data at EHA (streetinsider.com)
Several research firms recently commented on KPTI. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Karyopharm Therapeutics in a research report on Thursday, May 17th. Zacks Investment Research raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 17th. BidaskClub raised Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 17th. Canaccord Genuity raised their target price on Karyopharm Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, March 12th. Finally, Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 15th. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $21.10.
Shares of Karyopharm Therapeutics opened at $19.88 on Tuesday, Marketbeat.com reports. The stock has a market capitalization of $984.54 million, a price-to-earnings ratio of -7.07 and a beta of 3.62. Karyopharm Therapeutics has a 52-week low of $7.48 and a 52-week high of $20.39.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, May 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.11). The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $4.59 million. equities analysts anticipate that Karyopharm Therapeutics will post -3.15 EPS for the current fiscal year.
In other news, insider Sharon Shacham sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 9th. The stock was sold at an average price of $12.48, for a total value of $124,800.00. Following the transaction, the insider now owns 723,510 shares of the company’s stock, valued at $9,029,404.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Christopher Brett Primiano sold 2,500 shares of the firm’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $16.03, for a total value of $40,075.00. Following the completion of the transaction, the executive vice president now directly owns 4,881 shares in the company, valued at approximately $78,242.43. The disclosure for this sale can be found here. Insiders sold 67,000 shares of company stock worth $1,067,320 over the last three months. Insiders own 13.26% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.